Imunon has released data from the Phase II OVATION 2 study of its interleukin-12 (IL-12) immunotherapy called IMNN-001 in patients with advanced ovarian cancer. 30 July 2024
BioNTech released positive top-line data from the ongoing Phase II clinical trial in patients with unresectable stage III or IV melanoma whose disease had progressed following anti-PD-(L)1-containing treatment. 30 July 2024
Cognition Therapeutics (Nasdaq: CGTX) has announced disappointing results from its Phase II SHINE study for the drug CT1812, aimed at treating Alzheimer's disease. 30 July 2024
Shares in North Carolina, USA-based vTv Therapeutics (Nasdaq: VTVT) have fallen over a quarter after the firm announced a clinical hold on its diabetes program. 30 July 2024
The US Food and Drug Administration (FDA) has given its approval to Alpha Cognition’s oral therapeutic, Zunveyl (benzgalantamine), for the treatment of Alzheimer's disease (AD). 30 July 2024
USA-based brain health biotech Mind Medicine (MindMed; Nasdaq: MNMD) announced the appointment of Stephanie Fagan as Chief Corporate Affairs Officer. 30 July 2024
Dutch drug developer NewAmsterdam Pharma today announced what it called positive top-line data from the company’s Phase III BROOKLYN clinical trial (NCT05425745). 29 July 2024
GSK and USA-based biotech incubator Flagship Pioneering have entered a collaboration with the goal of discovering and developing a portfolio of future transformational medicines and vaccines. 29 July 2024
Belgian clinical-stage G-protein coupled receptor (GPCR) company Confo Therapeutics today announced the closing of a 60 million euros Series B financing 26 July 2024
US clinical-stage biotech Immunome has announced exclusive license agreement with Israel-based Nectin Therapeutics for rights to a panel of antibodies targeting an undisclosed target. 26 July 2024
Zymeworks has appointed Leone Patterson as executive vice president, and chief business and financial officer, effective September 1, 2024. 26 July 2024
Mid-size French drugmaker Ipsen and California’s Day One Biopharmaceuticals have announced a global partnership, outside the USA, for tovorafenib. 25 July 2024
The appointment of Dr Sicard comes at a time when the company has selected its lead candidate, DGX-01, a first-in-class recombinant protein that aims to replicate insulin-producing beta cells in t 25 July 2024
Cambridge, Massachusetts-based Pinetree Therapeutics has entered into an exclusive option and global license agreement with Cambridge, UK-based AstraZeneca . 25 July 2024
Sage Therapeutics’ shares plunged nearly 22% to $10.25 in pre-market activity, as it announced disappointing top-line results from the Phase II KINETIC 2 dose-range study of the oral investigational drug SAGE-324 (BIIB124) as a potential treatment in essential tremor (ET). 24 July 2024
Trevi Therapeutics has announced significant milestones in its clinical programs for Haduvio (nalbuphine), an investigational therapy aimed at treating chronic cough in idiopathic pulmonary fibrosis (IPF) and refractory chronic cough (RCC). 4 October 2024
Paris-based asset manager Kurma Partners has raised 140 million euros ($154 million), successfully completing the first closing of Biofund IV 4 October 2024
Singapore’s Agency for Science, Technology and Research (A*STAR) and US biotech incubator Flagship Pioneering have agree to collaborate on advancing health and sustainability outcomes in Singapore and the broader Asia Pacific region. 4 October 2024
The US Food and Drug Administration (FDA) has removed the partial clinical hold on delpacibart etedesiran (del-desiran/AOC 1001), an investigational treatment designed to address the root cause of myotonic dystrophy type 1 (DM1), under development by US biotech Avidity Biosciences . 4 October 2024
Caliway Biopharmaceuticals has successfully completed its initial public offering, raising NT$6.4 billion ($206 million), the largest IPO in Taiwan's biotech industry to date. 3 October 2024
US clinical-stage biotech Arcus Biosciences has entered into a clinical trial collaboration with AstraZeneca on renal cancer treatments. 3 October 2024
PeptiDream says that its wholly-owned PDRadiopharma subsidiary has entered into a strategic partnership with French nuclear medicines firm Curium. 3 October 2024
Shares of UK drug developer Hemogenyx Pharmaceuticals rose as much as 9% and closed up 5.9% at 1.70 pence yesterday on the news of a further investment from Prevail Partners. 3 October 2024
UK-based biotech Resolution Therapeutics has announced the completion of a £63.5 million ($76.8 million) series B financing round led by Syncona. 3 October 2024
Liquidia Corporation and Pharmosa Biopharm have amended the current exclusive licensing agreement for the development and commercialization of L606. 3 October 2024
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
UK-based biotech LoQus23 Therapeutics has closed a £35 million ($43 million) series A financing round, led by Forbion, with support from SV Health Investors' Dementia Discovery Fund and Novartis Venture Fund. 2 October 2024
Privately-held UK biotech Curve Therapeutics today announced the further strengthening of its leadership team with the appointments of Andre Hoekema as chairman of the board and Cora Griffin as head of business development. 2 October 2024
NK:IO, a London startup developing a cell therapy for treating solid tumors, has announced the appointment of a permant chief executive and the finalization of a seed funding round. 2 October 2024
Spanish epigenetics firm Oryzon Genomics has announced the receipt of the official meeting minutes from a recent End-of-Phase II meeting for vafidemstat in borderline personality disorder (BPD) with the US Food and Drug Administration (FDA). 2 October 2024
Halda Therapeutics, a US biotech company advancing cancer treatments, announced the appointment of Christian Schade as president and chief executive. 1 October 2024